Down 10% in a month, are CSL shares feeling the sting of a potential disruption?

Brokers are still bullish.

| More on:
Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) shares have slipped 9.77% over the past month, leaving some investors questioning whether the global biotech heavyweight is facing new headwinds.

This comes as international stock markets roar to new heights following the outcome of the recent US election.

Despite this, CSL shares have been heavily sold. At the time of writing, they are trading near three-month lows at $272.30 apiece.

With the company reaffirming robust FY25 guidance, is now a golden buying opportunity or a warning sign for ASX investors? Let's see.

Created with Highcharts 11.4.3CSL PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

What's behind the dip in CSL shares?

The slide in CSL shares coincides with a selloff in the broader healthcare sector, likely fuelled by geopolitical and regulatory concerns.

Today, healthcare stocks as a basket are down more than 1%, joined by the IT and financial sectors, which are also in the red.

Meanwhile, reports have surfaced surrounding US president-elect Donald Trump's choice to head the US Department of Health and Human Services: Robert F Kennedy Jr (or RFK as he is known).

Reporting from The Guardian says that global pharmaceuticals stocks sold off last week after the news was announced.

"The potential ramifications of RFK Jr running the department prompted panic among investors with shares [in pharmaceutical stocks]," it said.

Wait, what? Hold up a moment…

Let's take a step back here for a second and nut out how this relates to CSL shares.

A fundamental principle in statistics is that correlation does not (emphasis added) equal causation.

For instance, there could be an increasing trend for the number of sunny days in a year and the number of cats falling off rooftops.

Does that mean sunny days cause cats to fall off roofs? Or, that cats falling off rooftops causes the sun to shine? No.

The appointment of an elected official does not change a business's fundamental outlook, at least not overnight.

The same is true for CSL shares.

Brokers are bullish

That's why, while these factors may have spooked investors in the very short term, analysts remain bullish on the outlook for CSL shares.

At the company's annual general meeting in October, management reaffirmed FY25 guidance, projecting net profit between US$3.2 billion and US$3.3 billion.

This equates to growth of 10% to 13% — a sign that the biotech continues to deliver strong fundamentals despite market turbulence, supporting growth in CSL shares.

CSL's guidance has been met with widespread confidence from brokers.

Ord Minnett rates CSL shares as a buy, citing its margin recovery phase and consistent earnings growth. Analyst Tony Paterno noted that fluctuating exchange rates might shave off around US$50 million from FY25 figures, but this impact was expected to be minimal.

Bell Potter also sees potential upside, noting that CSL currently trades at a discount to its 10-year average forward price-to-earnings (P/E) ratio of 311 times.

Meanwhile, Citi has set a bullish price target of $345 for CSL shares, implying plenty of upside from current levels.

Finally, Morgans has also thrown its weight behind CSL shares, forecasting annual double-digit earnings growth over the mid-term.

Should you buy CSL shares now?

While the recent dip in CSL shares might unsettle some investors, the company's fundamentals remain strong.

On that point, it's essential to keep a long-term view in mind. Markets will overreact to the upside and downside, providing opportunities.

More important are the factors of business valuation, performance and the broader economy – not the headlines.

In the last 12 months, the stock is up 5.3%.

Should you invest $1,000 in CSL right now?

Before you buy CSL shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and CSL wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 7 February 2025

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
Healthcare Shares

Why is the Sigma share price soaring 6%?

Sigma has upgraded its FY25 guidance ahead of the anticipated Chemist Warehouse merger completion.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Which ASX 200 healthcare share will pay the best dividend yield in 2025?

Earnings season is underway and dividend announcements are on investors' minds.

Read more »

A person is weighed down by a huge stack of coins, they have received a big dividend payout.
Dividend Investing

Looking to bag the record high ResMed dividend? You better hurry!

Unlike the majority of ASX 200 income stocks, ResMed pays dividends every quarter.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

3 reasons to buy CSL shares today

Two investment experts expect a big turnaround for CSL shares in 2025.

Read more »

Business people discussing project on digital tablet.
Healthcare Shares

Down 4%, is the ResMed share price in the buy zone?

Do analysts think investors should be buying the dip? Let's see what they are saying.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Guess which ASX 100 share is sinking 8% because of Trump's tariffs

Donald Trump has dealt this company a big blow. What's happening?

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Up 1,090% in a year, why is the Mesoblast share price leaping higher again on Friday?

Mesoblast shares have surged more than 1,000% over the last 12 months.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Earnings Results

ResMed shares rise on strong Q2 result

Let's see how this sleep treatment company performed during the second quarter.

Read more »